Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Bicara Therapeutics Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Research and development
30.6
63.6
General and administrative
9.27
18.8
30.5
Operating expenses
39.9
82.4
156
Operating income
-39.9
-82.4
-156
Interest income
1.31
14.6
17.9
Other non-operating income
-12.1
14.6
17.9
Pre-tax income
-52
-67.8
-138
Income tax
0.01
0.19
0.22
Net income
-52
-68
-138
EBITDA
-39.9
-82.3
-155
EPS, basic
-89.61
-4.05
-2.52
EPS, diluted
-89.61
-4.05
-2.52
Shares, basic (weighted)
580
16,806
54,677
Shares, diluted (weighted)
580
16,806
54,677
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
230
490
96.7
Short-term investments
0
318
Other current assets
0.63
12.8
7.25
Total current assets
231
503
422
Property, plant and equipment
0.2
0.16
0.33
Lease right-of-use assets
0.61
0.69
1.7
Long-term investments
0
Other non-current assets
2.09
6.62
6.91
Total assets
234
510
431
Accrued liabilities
8.05
12.9
5.04
Total current liabilities
15.1
18
28.9
Lease liabilities
0.37
0.13
0.59
Other non-current liabilities
0.02
0
Total liabilities
15.5
18.1
29.5
Paid-in capital
4.25
713
760
Retained earnings
-153
-221
-359
Other comprehensive income
0
0.24
Shareholders' equity
-149
492
401
Total equity
-149
492
401
Total liabilities and equity
234
510
431
Shares outstanding
0.64
54.4
56.6
Cash flow statement
FY2024
FY2024
FY2025
Net income
-52
-68
-138
Depreciation and amortization
0.02
0.06
0.11
Stock-based compensation
1.9
7.4
15
Deferred income tax
0
0
0
Cash from operations
-45.6
-74.8
-107
Capital expenditures
-0.59
-0.07
-0.28
Purchases of investments
0
-318
Cash from investing
-0.59
-0.01
-318
Stock issued
0
332
29.5
Cash from financing
272
334
32.3
Net change in cash
226
259
-393
Free cash flow
-46.2
-74.8
-107
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $19.21 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-39.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-36.2%
Net income / average total assets.
Return on invested capital (ROIC)
-42.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-18.4%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-15.5%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
225.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
11.6x
Current assets / current liabilities.
Quick ratio
11.4x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
11.4x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.99
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.99
Cash from operations / diluted weighted shares.
Book value per share
$7.11
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
2.71x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.71x
Market cap / tangible book value, when positive.
FCF yield
-10.6%
Free cash flow / market cap.
Earnings yield
-14.6%
Net income / market cap (the inverse of P/E).
Was Bicara Therapeutics Inc. profitable in fiscal 2025?
No. It reported a net loss of $138.0M.
How much free cash flow did Bicara Therapeutics Inc. generate in fiscal 2025?
Cash from operations of $106.8M minus capital expenditures of $280.0K left free cash flow of -$107.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.